[go: up one dir, main page]

HRP20190486T1 - Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom - Google Patents

Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom Download PDF

Info

Publication number
HRP20190486T1
HRP20190486T1 HRP20190486TT HRP20190486T HRP20190486T1 HR P20190486 T1 HRP20190486 T1 HR P20190486T1 HR P20190486T T HRP20190486T T HR P20190486TT HR P20190486 T HRP20190486 T HR P20190486T HR P20190486 T1 HRP20190486 T1 HR P20190486T1
Authority
HR
Croatia
Prior art keywords
compound according
amino acid
conjugated compound
cysteine
antibody
Prior art date
Application number
HRP20190486TT
Other languages
English (en)
Inventor
Changshou Gao
Godfrey Rainey
Cuihua Gao
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of HRP20190486T1 publication Critical patent/HRP20190486T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

1. Konjugirani spoj koji sadrži cisteinsko protutijelo dobiveno inženjeringom ili Fc fuzijski protein i najmanje jedan heterologni ostatak, naznačen time što: (i) Fc domena protutijela ili Fc fuzijski protein obuhvaća umetanje cistein aminokiseline između položaja 239 i 240, pri čemu je numeriranje položaja aminokiseline prema EU indeksu kako je navedeno u Kabatu; i (ii) pri čemu je najmanje jedan heterologni ostatak konjugiran na cistein aminokiselinu koja je umetnuta između položaja 239 i 240.
2. Konjugirani spoj prema zahtjevu 1 naznačen time što nadalje sadrži jedan ili više cisteina dobivenih inženjeringom na 241, 243, 251, 253, 258, 264, 269, 271, 272, 274, 280, 281, 285, 288, 291, 293, 294, 296, 301, 307, 309, 311, 318, 329, 340, 341, 345, 357, 385, 386, 387, 401, 402, 411, 417, 433, 435, ili 439 pri čemu je numeriranje položaja aminokiseline prema EU indeksu kako je navedeno u Kabatu.
3. Konjugirani spoj prema zahtjevu 2, naznačen time što je inženjeringom dobivena cisteinska aminokiselina odabrana od supstitucija cisteinske aminokiseline na položajima aminokiselina 241, 243, 251, 253, 258, 264, 271, 285, 288, 291, 296, 301, 307, 309, 311, 329, 385, 387, 433, ili 435, i njihovih kombinacija.
4. Konjugirani spoj prema zahtjevu 2, naznačen time što je inženjeringom dobivena cisteinska aminokiselina odabrana od supstitucija cisteinske aminokiseline na položajima aminokiselina 258, ili 435, i njihovih kombinacija.
5. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time što sadrži: Cistein (C) umetnut između Serina (S) koji se nalazi na položaju 239 i Valina (V) koji se nalazi na položaju 240; i (a) Cistein (C) koji zamjenjuje glutaminsku kiselinu (E) koja se nalazi na položaju 258; (b) Cistein (C) koji zamjenjuje histidin (H) koji se nalazi na položaju 435; (c) Cistein (C) koji zamjenjuje arginin (R) koji se nalazi na položaju 435; ili (d) njihovu kombinaciju, pri čemu je numeriranje položaja aminokiseline prema EU indeksu kako je navedeno u Kabatu.
6. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time što Fc domena nadalje sadrži najmanje jedan cisteinski ostatak dobiven inženjeringom odabran od cisteinskih aminokiselinskih supstitucija na položajima aminokiselina 239, 248, 254, 273, 279, 282, 284, 286, 287, 289, 297, 298, 312, 324, 326, 330, 335, 337, 339, 350, 355, 356, 359, 360, 361, 375, 383, 384, 389, 398, 400, 413, 415, 418, 422, 440, 441, 442, 443 i 446.
7. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time što je svaki od heterolognih ostataka konjugiran na cistein dobiven inženjeringom.
8. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time što Fc domena protutijela ili Fc fuzijski protein je ljudska IgG Fc domena, proizvoljno odabrana iz skupine koja se sastoji od IgG Fc domene od IgG1, IgG2, IgG3, ili IgG4.
9. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time što Fc fuzijski protein odabrana iz skupine koja se sastoji od domenu koja veže antigen sele odabranu iz skupine koju čine: (a) scFv; (b) diatijelo; (c) Fd fragment; (d) Fv fragment; (e) F(ab')2 fragment; i (f) F(ab) fragment.
10. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time što protutijelo je a monoklonsko protutijelo, bispecifično protutijelo, multispecifično protutijelo, kimerno protutijelo, ljudsko protutijelo, ili humanizirano protutijelo.
11. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time što najmanje jedan heterologni ostatak je toksin, lijek, radionuklid, imunomodulator, citokin, limfokin, kemokin, faktor rasta, faktor nekroze tumora, hormon, antagonist hormona, enzim, oligonukleotid, DNA, RNA, siRNA, RNAi, mikroRNA, peptidna nukleinska kiselina, fotoaktivno terapijsko sredstvo, anti-angiogeno sredstvo, pro-apoptotičko sredstvo, ne-prirodna amino kiselina, peptid, lipid, ugljikohidrat, skeletna molekula, fluorescentna oznaka, vizualizacijski peptid, biotin, produživač poluživota u serumu, oznaka za hvatanje, sredstvo za keliranje, kruta podloga, ili njihova kombinacija, te pri čemu se konjugacija nalazi na jednom od cisteina dobivenih inženjeringom.
12. Konjugirani spoj prema zahtjevu 11, naznačen time što je lijek auristatin, tubulizin, a pirolobenzodiazepin (PBD) ili majtanzinoid.
13. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 12, naznačen time što se cisteinsko protutijelo dobiveno inženjeringom ili Fc fuzijski protein veže na najmanje jednu metu.
14. Konjugirani spoj prema zahtjevu 13, naznačen time što je meta tumorski antigen i heterologni dio je antitumorsko sredstvo.
15. Konjugirani spoj prema bilo kojem od zahtjeva 1 do 14 naznačen time što je za uporabu u terapiji.
HRP20190486TT 2014-04-11 2015-04-10 Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom HRP20190486T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978481P 2014-04-11 2014-04-11
PCT/US2015/025237 WO2015157595A1 (en) 2014-04-11 2015-04-10 Conjugated compounds comprising cysteine-engineered antibodies
EP15777039.7A EP3129406B1 (en) 2014-04-11 2015-04-10 Conjugated compounds comprising cysteine-engineered antibodies

Publications (1)

Publication Number Publication Date
HRP20190486T1 true HRP20190486T1 (hr) 2019-05-31

Family

ID=54288421

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190486TT HRP20190486T1 (hr) 2014-04-11 2015-04-10 Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom

Country Status (21)

Country Link
US (2) US10744204B2 (hr)
EP (1) EP3129406B1 (hr)
JP (1) JP6685924B2 (hr)
CN (1) CN106459205B (hr)
AU (1) AU2015243380B2 (hr)
BR (1) BR112016023436A2 (hr)
CA (1) CA2944784A1 (hr)
CY (1) CY1122155T1 (hr)
DK (1) DK3129406T3 (hr)
ES (1) ES2719584T3 (hr)
HR (1) HRP20190486T1 (hr)
HU (1) HUE041976T2 (hr)
LT (1) LT3129406T (hr)
PL (1) PL3129406T3 (hr)
PT (1) PT3129406T (hr)
RS (1) RS58440B1 (hr)
RU (1) RU2711485C2 (hr)
SI (1) SI3129406T1 (hr)
SM (1) SMT201900160T1 (hr)
TR (1) TR201903526T4 (hr)
WO (1) WO2015157595A1 (hr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP3107563B1 (en) 2014-02-21 2021-04-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3129055B1 (en) 2014-04-11 2020-07-01 MedImmune, LLC Bispecific her2 antibodies
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
MA42250B1 (fr) * 2015-06-29 2020-11-30 Immunogen Inc Conjugués d'anticorps à cystéine modifiée
SG10202103712VA (en) * 2015-11-10 2021-05-28 Medimmune Llc Binding molecules specific for asct2 and uses thereof
EP3383420B1 (en) 2015-12-04 2022-03-23 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
BR112018012524A2 (pt) 2015-12-21 2018-12-11 Bristol Myers Squibb Co anticorpos variantes para conjugação sítio-específica
JP7088454B2 (ja) * 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
DE102016106271B4 (de) * 2016-04-06 2018-03-29 Axagarius Gmbh & Co. Kg Aufreinigung von Nukleinsäure aus einer Nukleinsäure und Endotoxin enthaltenden Probe
JP7011764B2 (ja) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体アジュバント複合体
CN106938051B (zh) 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
AU2017327369A1 (en) 2016-09-13 2019-05-02 Allergan, Inc. Stabilized non-protein Clostridial toxin compositions
CN118846112A (zh) * 2016-10-08 2024-10-29 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物及其制备方法
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
WO2018085769A1 (en) 2016-11-07 2018-05-11 Seattle Genetics, Inc. Distribution of engineered-cysteine caps
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
BR112019015044A2 (pt) * 2017-02-08 2020-03-10 Pfizer Inc. Processo de produção em grande escala para cisteínas de anticorpo capeadas e não capeadas e seu uso na conjugação de proteínas terapêuticas
EP3589320A4 (en) 2017-02-28 2020-12-23 Seagen Inc. ANTIBODIES UNDERGOING CYSTEINE MUTATION FOR CONJUGATION
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN117603148A (zh) 2017-05-05 2024-02-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
NZ759831A (en) 2017-05-05 2025-05-30 Centre For Probe Dev And Commercialization Igf-1r monoclonal antibodies and uses thereof
AU2018281045A1 (en) * 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
JP7153082B2 (ja) * 2017-06-20 2022-10-13 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． システイン改変抗体－毒素複合体（ｔｄｃ）の部位特異的結合サイトのスクリーニング
CN107167540B (zh) * 2017-07-08 2019-07-30 万舒（北京）医药科技有限公司 测定人尿液生物样品中的DTPA-Zn的方法
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
WO2019046858A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF
CA3073560A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
CN111683963B (zh) * 2017-10-03 2024-03-29 默克专利有限公司 半胱氨酸工程化的抗原结合分子
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
KR102771546B1 (ko) * 2017-11-08 2025-02-21 야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 생체분자의 컨쥬게이트 및 이의 용도
ES2920123T3 (es) 2017-11-14 2022-08-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2022513400A (ja) * 2018-10-29 2022-02-07 メルサナ セラピューティクス インコーポレイテッド ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
CA3124129A1 (en) * 2018-12-21 2020-06-25 Sapreme Technologies B.V. Saponin conjugated to epitope-binding proteins
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
KR20250056898A (ko) 2019-02-15 2025-04-28 우시 엑스디씨 싱가포르 프라이빗 리미티드 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
US11833214B2 (en) * 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
US20220249389A1 (en) 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
CA3139714A1 (en) 2019-07-12 2021-01-21 Wassana Yantasee Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
WO2021014026A2 (en) * 2019-07-25 2021-01-28 Sapreme Technologies B.V. Bioactive saponin linked to a functional moiety
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
US11879004B2 (en) * 2020-02-28 2024-01-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
IL299354A (en) * 2020-06-24 2023-02-01 Sapreme Tech Bv Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof
CN111978571B (zh) * 2020-07-09 2021-08-03 北京师范大学 一种荧光可调的含铕配位聚合物水凝胶薄膜
CN113913404A (zh) * 2020-07-10 2022-01-11 上海米然生物科技有限公司 一种荧光交联RNase H突变体缀合物及其应用
CN112225813B (zh) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 针对破伤风毒素的抗体及其用途
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024510526A (ja) * 2021-03-26 2024-03-07 サイムワークス・ビーシー・インコーポレイテッド システイン操作された抗体コンストラクト、コンジュゲート、及び使用方法
RU2770003C1 (ru) * 2021-04-05 2022-04-14 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к С-концевому фрагменту антимюллерова гормона
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2022232246A1 (en) * 2021-04-28 2022-11-03 Ngm Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant
RU2768044C1 (ru) * 2021-12-28 2022-03-23 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденоассоциированного вируса, обладающий защитными свойствами против интоксикации, вызванной ботулиническим нейротоксином типа А
CN118679260A (zh) 2022-02-09 2024-09-20 国立研究开发法人医药基盘·健康·营养研究所 与fcrl1结合的抗体或该抗体片段
CN115177751B (zh) * 2022-03-16 2023-07-04 北京药明博锐生物科技有限公司 缀合物、其制备方法和用途
WO2023240067A2 (en) * 2022-06-07 2023-12-14 Ngb Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant and mutations that reduce effector functions
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
CN117198390B (zh) * 2023-09-08 2024-03-12 中国科学院广州生物医药与健康研究院 通过设计和改造二硫键交联位点的slc膜蛋白复合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT2256134E (pt) * 2003-11-13 2014-03-05 Hanmi Science Co Ltd Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo
AU2006304387A1 (en) * 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
ES2523915T5 (es) * 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
EP2244729B1 (en) * 2008-01-18 2016-11-02 MedImmune, LLC Cysteine engineered antibodies for site-specific conjugation
ES2643446T3 (es) 2009-06-04 2017-11-22 Novartis Ag Métodos para la identificación de sitios para conjugación de IgG
BRPI1015234A2 (pt) * 2009-06-22 2018-02-20 Medimmune Llc regiões fc projetadas para conjugação sítio específica.
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
CN113527469A (zh) * 2012-02-09 2021-10-22 中外制药株式会社 抗体的Fc区变异体
PL2953976T3 (pl) * 2013-02-08 2021-11-02 Novartis Ag Specyficzne miejsca modyfikowania przeciwciał dla wytwarzania immunokoniugatów
CN117018219A (zh) * 2017-08-01 2023-11-10 免疫医疗有限责任公司 Bcma单克隆抗体-药物缀合物
CN110713666B (zh) * 2018-07-13 2022-03-18 杭州星庐科技有限公司 一种含氯橡胶组合物及其应用和制备方法

Also Published As

Publication number Publication date
RU2711485C2 (ru) 2020-01-17
HUE041976T2 (hu) 2019-06-28
CY1122155T1 (el) 2020-11-25
TR201903526T4 (tr) 2019-03-21
BR112016023436A2 (pt) 2017-10-17
RU2016144146A (ru) 2018-05-11
US20210069341A1 (en) 2021-03-11
PL3129406T3 (pl) 2019-07-31
RU2016144146A3 (hr) 2018-12-14
CA2944784A1 (en) 2015-10-15
RS58440B1 (sr) 2019-04-30
US20180169255A1 (en) 2018-06-21
JP2017512486A (ja) 2017-05-25
EP3129406A1 (en) 2017-02-15
US10744204B2 (en) 2020-08-18
CN106459205B (zh) 2021-04-09
PT3129406T (pt) 2019-04-24
AU2015243380A1 (en) 2016-11-10
SMT201900160T1 (it) 2019-05-10
EP3129406A4 (en) 2017-12-06
LT3129406T (lt) 2019-04-10
WO2015157595A1 (en) 2015-10-15
JP6685924B2 (ja) 2020-04-22
SI3129406T1 (sl) 2019-04-30
AU2015243380B2 (en) 2020-05-14
EP3129406B1 (en) 2019-01-09
DK3129406T3 (en) 2019-04-01
CN106459205A (zh) 2017-02-22
ES2719584T3 (es) 2019-07-11

Similar Documents

Publication Publication Date Title
HRP20190486T1 (hr) Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom
IL299072A (en) Antibodies and methods of use thereof
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20231578T1 (hr) Molekule protutijela na april i njihove uporabe
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
HRP20201091T1 (hr) Protutijela anti-axl
HRP20200882T1 (hr) Vezujuće molekule specifične za asct2 i njihova uporaba
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
HRP20201031T1 (hr) Anti-ctla-4 protutijela i postupci njihove upotrebe
JP2017149720A5 (hr)
HRP20210602T1 (hr) Vezujuće molekule koje vežu pd-l1 i lag-3
JP2013121353A5 (hr)
HRP20200887T1 (hr) Smjese za inhibiciju masp-2 ovisne aktivacije komplementa
HRP20211444T1 (hr) Anti-dll3 antitijelo
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
RU2014120757A (ru) Связывающие молекулы, специфичные по отношению к her3, и их применения
JP2015506912A5 (hr)
JP2019519492A5 (hr)
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
HRP20220553T1 (hr) Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
CN104203982A (zh) 多肽构建体及其用途
HRP20221088T1 (hr) Protutijela i postupci uporabe
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
JP2017507936A5 (hr)